Get the Weekly Intelligence Brief — top committee picks every Sunday.

CVSA vs SYY

Covista Inc. vs Sysco Corporation — AI-powered side-by-side comparison
CVSA
Covista Inc.
62
Buy
VS
SYY
Sysco Corporation
54
Watch
MetricCVSASYY
AI Score 62 54
Price $136.52 $83.46
P/E Ratio 17.58× 22.85×
ROE 17.4% 65.9%
Revenue Growth YoY
Gross Margin 57.3% 18.5%
Debt / Equity 0.63× 5.61×
Dividend Yield 0.0% 2.6%
RSI (14) 56.5 56.1
Beta 0.623 0.636
Expected Upside +0.6% +9.5%

AI Committee View

Current Innellis committee reasoning for CVSA versus SYY.
CVSA leads by 8 points.

CVSA scores 62/100 (Buy) versus SYY at 54/100 (Watch).

CVSA Committee View
67% agreement
6 analysts

The primary driver is news sentiment is positive (+0.50 across 2 articles, 14d). The main limiting factor is current ratio of 0.82 is tight -- limited short-term liquidity cushion. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 16.6% shows genuine earnings power backing the valuation — Value
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Current ratio of 0.82 is tight -- limited short-term liquidity cushion — Risk
SYY Committee View
50% agreement
6 analysts

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 24 articles, 14d). Risk Analyst remains cautious — high leverage (debt-to-equity 5.07) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 75.4% shows genuine earnings power backing the valuation — Value
  • Dividend yield of 2.8% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Price-to-book of 15.0x prices in significant intangible value — Value
  • Debt-to-equity of 5.07 adds balance-sheet risk to the value case — Value
  • EPS declining -2.1% YoY despite any revenue growth — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
CVSA Full Analysis SYY Full Analysis